Illumina reunites with cancer testing firm Grail, worth $8 billion deal
FierceBiotech - 21-Sep-2020Marks new era in advancing screening and early diagnosis of cancer technology
Join the club for FREE to access the whole archive and other member benefits.
Sequencing and array-based solutions for analysis of genetic variation and function
Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Visit website: https://www.illumina.com/
Details last updated 06-Mar-2020
Marks new era in advancing screening and early diagnosis of cancer technology
Demonstrated in a large prospective study involving patients without cancer history
Not here yet, but will expand research capabilities and change the way medicine is practiced